GlassScriptPhysician profile
Hillary Maxine Ottenbaker
NPI 1689281396
$4,346.75
in general payments reported to CMS, 2019-2025
21 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $894 · 2023: $1,474 · 2024: $905 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.71 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $925.95 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $443.78 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $431.10 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $331.98 | 2022-2024 | |
| Medline Industries LP | $320.26 | 2023-2025 | |
| Abbvie INC. | $297.36 | 2021-2024 | |
| Astellas Pharma US INC | $295.47 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.83 | 2021-2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $210.90 | 2021-2023 | |
| Lilly USA, LLC | $153.05 | 2022-2024 | Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $124.99 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $116.64 | 2021 | |
| Medtronic, INC. | $115.83 | 2022 | |
| Idorsia Pharmaceuticals US INC | $74.55 | 2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $54.59 | 2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $21.89 | 2024 | Rexulti |
| Grifols USA, LLC | $20.32 | 2023 | Prolastin-C Liquid |
| Dexcom, INC. | $18.96 | 2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $16.06 | 2023 | Tlando, Nocdurna, Xyosted |
| Philips North America LLC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Ottenbaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.